GLOBAL CANCER THERAPEUTICS AND BIOTHERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In May 2024, biotechnology investors contributed US$ 200 million to the spin-out of BridgeBio Pharma, which is now known as BridgeBio Oncology Therapeutics. Previously known as TheRas under BridgeBio, this spinout is focused on creating medications that target mutations in the KRAS gene, which are common in malignancies of the lung, colon, and pancreas.
• On March 2024, the clinical-stage biopharmaceutical business Fusion Pharmaceuticals Inc., which is creating next-generation radioconjugates (RCs), and AstraZeneca, pharama company reached a definitive agreement for the latter's acquisition. Using more tailored treatments in place of conventional regimens like chemotherapy and radiation, the acquisition represents a significant advancement toward AstraZeneca's goal of revolutionizing cancer treatment and patient outcomes.
• In January 2023, Bridge Biotherapeutics, a biotech company, and Pinotbio entered into a strategic partnership focused on advancing novel cancer therapeutics through Antibody-Drug Conjugates (ADCs). ADCs represent precision medicines that merge the specificity of monoclonal antibodies with the cytotoxicity of chemotherapeutic agents. This collaboration aims to harness the strengths of both companies to accelerate the development of next-generation ADCs, enhancing efficacy, safety, and tolerability in cancer treatment.
• In June 2023, Cambrian Bio launched Telos Biotech, a subsidiary dedicated to pioneering advanced cell therapies. Drawing on its expertise in cell biology and genome engineering, Cambrian Bio aims to develop robust and more effective cell therapies capable of addressing a broad spectrum of diseases and medical conditions.
• In July 2022, Exelixis, Inc. and Ryvu Therapeutics S.A. (Warsaw Stock Exchange: RVU) entered an exclusive license agreement focused on developing targeted therapies utilizing Ryvu’s STING (STimulator of INterferon Genes) technology. This collaboration aims to integrate Ryvu’s small molecule STING agonists and expertise in STING biology with Exelixis’ capabilities in antibody engineering, antibody-drug conjugate (ADC) technologies, and its track record in oncology therapeutics development and commercialization.
• In June 2021, Genmab A/S and Bolt Biotherapeutics, Inc. initiated an oncology research and development collaboration. This partnership aims to combine Genmab's antibodies and bispecific antibody engineering technologies with Bolt's Boltbody immune-stimulating antibody conjugate (ISAC) platform.